EMEA-000157-PIP01-07-M05
Key facts
| Invented name |
Nulojix
|
| Active substance |
belatacept
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/0277/2020
|
| PIP number |
EMEA-000157-PIP01-07-M05
|
| Pharmaceutical form(s) |
Powder for concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Prevention of rejection of transplanted kidney
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Bristol-Myers Squibb Pharma EEIG
E-mail: medical.information@bms.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|